학술논문

Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases
Document Type
Source
Allergy: European Journal of Allergy and Clinical Immunology. 74(11):2064-2076
Subject
allergic diseases
asthma
big data
environmental health
exposome
implementation science
quality criteria
translational research
Samhällsvetenskap
Annan samhällsvetenskap
Tvärvetenskapliga studier inom samhällsvetenskap
Social Sciences
Other Social Sciences
Social Sciences Interdisciplinary
Medicin och hälsovetenskap
Hälsovetenskap
Hälso- och sjukvårdsorganisation
hälsopolitik och hälsoekonomi
Medical and Health Sciences
Health Sciences
Health Care Service and Management
Health Policy and Services and Health Economy
Medicinsk etik
Medical Ethics
Language
English
ISSN
0105-4538
Abstract
The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.